How to improve outcomes in Chronic Kidney Disease
Paul CockwellConsultant Nephrologist
Queen Elizabeth Hospital Birmingham
CKD is usually present in association with other chronic conditions
0
5
10
15
20
25
30
Haza
rd R
atio
of D
eath
Number of co-morbidities0 1 2 43 65
Heart of Birmingham PCT – Relative risk of death based on known comorbidities
Aims of the lecture
• To discuss risk stratification in CKD
• Outline the current evidence base for the management of CKD
• Discuss the relevance of AKI to CKD
Estimated prevalence of CKD in the UK is 13.5% - based on single tests
– 6% with stage 3-5 CKD (eGFR <60 ml/min)
– 9% with albuminuria
eGFR – brief summary• aMDRD – current internationally accepted standard for reporting
kidney function when the eGFR is abnormal (<60 ml/min)– aMDRD factors 4 variables – age, sex, ethnicity and creatinine – to
provide an eGFR
• Cockroft Gault eGFR – often used for drug dose adjustment– CG and MDRD eGFR are not equivalent
• CKD EPI eGFR – a new generation eGFRs that may supersede MDRD
Beware of the (inaccuracy) of eGFR
eGFR is not accurate when ≥ 60 mL/min
Greatest accuracy at 30–59 mL/min; even then ‘90% of eGFRs within 30% of iGFR’!!
Poggio et al. J Am Soc Nephrol. 2005; 16: 459–4667
The Health improvement Network (THIN): 6.7 million patients from 426 primary care centres in the UK. CKD 3-5 prevalence 2005-2009.
Jain, Calvert, Cockwell, McManus – under review
For patients with an eGFR <60 ml/min delta eGFR is as important as
the overall value
Proteinuria
When the term proteinuria is used people are usually referring to albuminuria
Albuminuria in clinical practice is now measured by a urinary Albumin Creatinine Ratio
An ACR of 100 = an AER of 1g/d
The CKD classification system
The Health improvement Network (THIN): 6.7 million patients from 426 primary care centres in the UK. Age stratified prevalence of CKD 3-5 in 2009.
Jain, Calvert, Cockwell, McManus – manuscript under review
The CKD classification system
O’Hare et al, JASN 2007
eGFR threshold and risk of Death or ESKD
Risk of ESKD in respect of eGFR and proteinuria
ACR < 3mg/mmol
ACR 3-29 mg/mmol
ACR 30+ mg/mmol
Adapted from Levey et al KI 2011
Primary Care CKD
• Risk stratification
• BP management
• Primary and secondary prevention of CVD
• Monitoring
• Referral into and communication with secondary care
Secondary Care - Nephrology
• Manage the established renal failure pathway– Enhanced monitoring and counseling– Prepare for dialysis– Assess for kidney transplantation
• Manage secondary complications of kidney disease– Anemia of CKD (ESA, functional iron deficiency)– Secondary hyperparathyroidism
Secondary Care non-nephrology
• Management of comorbidity
• Drug dosing and toxicity
• Management of AKI
• Sense check for primary care
• Referral to secondary care nephrology
Issue date: September 2008
NICE clinical guideline 73 Developed by the National Collaborating Centre for Chronic Conditions
Chronic kidney disease Early identification and management of chronic kidney disease in adults in primary and secondary care
http://www.nice.org.uk/Guidance/CG73
Overall supporting information for the management of CKD
Minimising the risk for people with CKD of progression of CKD and Cardiovascular disease (CVD)
1. The BP target for non-proteinuric CKD without diabetes is <140/85
2. The BP target for diabetes and CKD is <130/80
3. The BP target for proteinuric CKD (ACR>30) without diabetes is <130/80
4. ACE inhibitors or ARBs should be used in all people with diabetes and with microalbuminuria (ACR>3.5 mg/mmol in men and 2.5 mg/mmol in women) and all people without diabetes with an ACR>30 even if BP<130/80.
5. The dose of ACEi/ARB should be used at the maximum tolerated. ACEi and ARBs should not be used in combination.
6. If there is an eGFR decline of >25% on introduction of an ACEi/ARB or dose increase of an ACEi/ARB then the drug should be stopped and advice should be obtained from secondary care nephrology
7. Primary and secondary prevention of CVD should be optimised; statins, anti-platelet drugs, and warfarin are not contraindicated in CKD.
8. NSAIDs should not be used
Management of complications of CKD
9. People with CKD and a Hb < 10g/dl, who have had other causes of anaemia excluded should be considered for treatment of anaemia associated with CKD. Advice should be obtained from secondary care nephrology.
10. Please refer any uncertainties about bone chemistry through the advice and guidance portal
From: Vanessa MillerSent: Monday, March 05, 2012 1:13 PMTo: Paul CockwellCc: Barbara JoyceSubject: A&G
Please see the attached advice and guidance request.
This young lad came to see me with testicular pain. As part of the assessment I dipsticked his urine which came up as showing marked proteinuria. Subsequent ACR came back as slightly elevated at 6.6. I saw him on a further two occasions and his urine remained positive on dipstick. His renal profile came back normal; creatinine 88, and urea 3.8. CRP was also normal at 10 and he is normotensive with blood pressure of 117/68. There is no family history of renal disease.
I would be grateful for your opinion as to whether this needs any further investigation.
Yours sincerely,
eService (request)
eService (reply)Dear
Thanks for the referral.
This is probably orthostatic (postural) proteinuria. I would diptest or ACR the urine on an early morning specimen (first urine pass of the day) - if -ve or trace +ve reassure him. Orthostatic proteinuria is common in male adolescents and usually goes by the age of 30. If positive let me know and we should probably review him to make sure that there is no glomerular lesion.
Best wishesPaul (Cockwell)________________________________________
THIN and QOF CKD1Confirmed CKD108,911
Labelled CKD139,176
Miscoded60705
Uncoded30,440
Appropriately coded78471
Jain, Calvert, Cockwell, McManus – under review
Is this important? – Probably
If you have CKD and are on the register vs not on the register
• You have better BP control
• If you have diabetes, you have a better HbA1c
Meta Analysis: Lower Mean BP Results in Slower Rates of Decline in GFR in Diabetics and Non-Diabetics
95 98 101 104 107 110 113 116 119
r = 0.69; P < 0.05
MAP (mmHg)
GFR
(m
L/m
in/y
ear)
130/85 140/90
UntreatedHTN
0-2-4-6
-8-10-12-14
Parving HH, et al. Br Med J. 1989. Moschio G, et al. N Engl J Med. 1996.Viberti GC, et al. JAMA. 1993. Bakris GL, et al. Kidney Int. 1996.Klahr S, et al. N Eng J. Med 1994. Bakris GL. Hypertension. 1997.Hebert L, et al. Kidney Int. 1994. The GISEN Group. Lancet. 1997.Lebovitz H, et al. Kidney Int. 1994.
Bakris GL, et al. Am J Kidney Dis. 2000;36(3):646-661., www.hypertensiononline.org
Accurate measurement of BP is crucial
Validated BP – BPTru
Standard clinic BPs vs BPTru
BP management – NICE guidelines
ACEi or ARBs and the kidneys – the evidence base
• People with diabetes and and ACR> 2.5 (men) or 3.5 (women) irrespective of BP
• Non-diabetic people with CKD and hypertension and ACR >30
• Non-diabetic people with CKD and ACR > 70 mg/mmol irrespective of BP
• No evidence for dual blockade
In high risk groups ACEi/ARBs provide a 20% risk reduction in ESKD
From Weir, NephSap; Vol 5 No 10, 2011
ACE inhibitors and glomerular function
PGC
Efferent dilatation
Glomerular pressure
Proteinuria
Interstitial capillary density and renal outcome
Statins – the SHARP study
• History of chronic kidney disease– not on dialysis: elevated creatinine on 2 occasions
• Men: ≥1.7 mg/dL (150 µmol/L)• Women: ≥1.5 mg/dL (130 µmol/L)
– on dialysis: haemodialysis or peritoneal dialysis• Age ≥40 years• No history of myocardial infarction or coronary
revascularization• Uncertainty: LDL-lowering treatment not definitely
indicated or contraindicated
0 1 2 3 4 5 Years of follow-up
0
5
10
15
20
25
Prop
ortio
n su
fferin
g ev
ent (
%) Risk ratio 0.83 (0.74 – 0.94)
Logrank 2P=0.0022 Placebo
Eze/simv
SHARP: Major Atherosclerotic Events
SHARP: Cause-specific mortality
Risk ratio & 95% CIEvent PlaceboEze/simv
Eze/simvbetter
Placebobetter
(n=4620)(n=4650)
Coronary 91 (2.0%) 90 (1.9%) Other cardiac 162 (3.5%) 182 (3.9%) Subtotal: Any cardiac 253 (5.4%) 272 (5.9%) 7.4% SE 8.4
reduction (p=0.38) Stroke 68 (1.5%) 78 (1.7%)
Other vascular 40 (0.9%) 38 (0.8%) Subtotal: Any vascular 361 (7.8%) 388 (8.4%) 7.3% SE 7.0
reduction (p=0.30)
Cancer 150 (3.2%) 128 (2.8%) Renal 164 (3.5%) 173 (3.7%)
Other non-vascular
Subtotal: Any non-vascular 668 (14.4%) 612 (13.2%) 8.6% SE 5.8 increase (p=0.14)
Unknown cause 113 (2.4%) 115 (2.5%)
Total: Any death 1142 (24.6%) 1115 (24.1%) 1.9% SE 4.2 increase (p=0.65)
0.6 0.8 1.0 1.2 1.4
354 (7.6%) 311 (6.7%)
Risk ratio & 95% CIPlaceboEze/simv
Eze/simv better
Placebo better
(n=4620)(n=4650)
Non-dialysis (n=6247) 296 (9.5%) 373 (11.9%) Dialysis (n=3023) 230 (15.0%) 246 (16.5%)
Major atherosclerotic event 526 (11.3%) 619 (13.4%) 16.5% SE 5.4 reduction (p=0.0022)
0.6 0.8 1.0 1.2 1.4
SHARP: Major Atherosclerotic Eventsby renal status at randomization
No significant heterogeneity between non-dialysis and dialysis patients (p=0.25)
Key points!!
Around 50% of the increased mortality risk associated with conventional risk factors
However patients with CKD are less likely to be optimally treated for risk factors than patients without
CKD
With advanced CKD there is an increasing association with non-traditional risk-factors
Non-traditional risk factors and an evidence base
• Spironolactone – RCTs in process
• Bicarbonate – RCT in process
• Phosphate – phosphate binder RCT being commissioned
• Allopurinol – strong supportive evidence – needs an RCT!!
A major risk factor for CKD is AKI
Only one criteria is required to qualify for stage
Stage Serum creatinine criteria Urine output criteria
Stage 1 Increase serum creatinine of ≥0.3 mg/dL (≥26.4 μmol/L) or ≥1.5-2 times from baseline
<0.5 ml/kg/ hour for >6 hours
Stage 2 Increase serum creatinine to ≥2-3 times from baseline
<0.5 ml/kg/ hour for >12 hours
Stage 3 Increase serum creatinine to >3 times from baseline or ≥4.0 mg/dL (≥354 μmol/L) with an acute increase of at least 0.5mg/dL (44 μmol/L)or renal replacement therapy
<0.3 ml/kg/ hour for 24 hours or anuria for 12 hours
Mehta et al, Crit Care, 2007
Rise in creatinine during hospital admission
Multivariable odds ratiofor hospital mortality
≥ 0.3 mg/dL (26 μmol/L) 4.1
≥ 0.5 mg/dL (45 μmol/L) 6.5
≥ 1.0 mg/dL (90 μmol/L) 9.7
≥ 2.0 mg/dL (180 μmol/L) 16.4
Acute kidney injury, mortality, length of stay and costs in hospitalized patients• 19,982 patients admitted to academic medical centre• 9,205 patients with >1 creatinine results
Chertow et al. J Am Soc Nephrol. 2005; 16: 3365–3370
Multivariate analysis
50
Impact of AKI on Hospital Mortality
ESRD: end-stage renal disease Okusa MD et al. Clin J Am Soc Nephrol. 2009; 4: 520–522
Likelihood of ESRD after AKI
51
Conclusion
• Use eGFR and ACR to risk stratify for CKD
• 50% of the risk of adverse outcomes accompanying CKD is associated with conventional risk factors – optimise their management
• Focus your inpatient service on accurate AKI management